Cite
Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial.
MLA
Witzens-Harig, Mathias, et al. “Quality of Life during Maintenance Therapy with the Anti-CD20 Antibody Rituximab in Patients with B Cell Non-Hodgkin’s Lymphoma: Results of a Prospective Randomized Controlled Trial.” Annals of Hematology, vol. 88, no. 1, Jan. 2009, pp. 51–57. EBSCOhost, https://doi.org/10.1007/s00277-008-0560-2.
APA
Witzens-Harig, M., Reiz, M., Heiß, C., Benner, A., Hensel, M., Neben, K., Dreger, P., Kraemer, A., & Ho, A. (2009). Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial. Annals of Hematology, 88(1), 51–57. https://doi.org/10.1007/s00277-008-0560-2
Chicago
Witzens-Harig, Mathias, Monika Reiz, Christiane Heiß, Axel Benner, Manfred Hensel, Kai Neben, Peter Dreger, Alwin Kraemer, and Anthony Ho. 2009. “Quality of Life during Maintenance Therapy with the Anti-CD20 Antibody Rituximab in Patients with B Cell Non-Hodgkin’s Lymphoma: Results of a Prospective Randomized Controlled Trial.” Annals of Hematology 88 (1): 51–57. doi:10.1007/s00277-008-0560-2.